Neuberger Berman Group
MNPR icon

Neuberger Berman Group’s Monopar Therapeutics MNPR Stock Holding History

Neuberger Berman Group’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.11M Buy
55,194
+12,760
+30% +$790K ﹤0.01% 1043
2026
Q1 		$2.32M Buy
42,434
+9,887
+30% +$597K ﹤0.01% 1144
2025
Q4 		$2.13M Buy
+32,547
New +$2.66M ﹤0.01% 1159

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Neuberger Berman Group's MNPR Position: Q2 2026 in Review

Neuberger Berman Group increased its Monopar Therapeutics (MNPR) stake by 30% in Q2 2026, buying an estimated $790K and bringing the position to 55,194 shares worth $5.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1043.

Neuberger Berman Group first reported a position in MNPR in Q4 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Neuberger Berman Group held 55,194 shares of Monopar Therapeutics worth $5.11M as of Q2 2026.
  • Neuberger Berman Group bought 12,760 Monopar Therapeutics shares in Q2 2026, an estimated $790K.
  • Monopar Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1043 holding.
  • Neuberger Berman Group first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.